ライフサイエンスコーパス: animal test

1 ise as a replacement for standard adult live animal tests.

2 -departure (tPODs) as an alternative to live-animal tests.

3 date compounds are processed in cell-line or animal tests.

4 prioritizing chemicals for ED-related whole-animal tests.

5 lian- or avian-only models were confirmed by animal tests.

6 in vivo bioaccumulation assays and to reduce animal testing.

7 he 3R principle (reduce, replace, refine) of animal testing.

8 educing the dependency of risk assessment on animal testing.

9 e-consuming, and ethically questionable live animal testing.

10 al information experimentally often involves animal testing.

11 ry pipeline, currently involving large scale animal testing.

12 e novel drugs and drug combinations prior to animal testing.

13 suming and expensive cell culture assays and animal testing.

14 als has historically been undertaken through animal testing.

15 a, were the most effective means of reducing animal testing.

16 logical endpoints and mating studies used in animal testing.

17 integration potential, with reduced need for animal testing.

18 l chemicals and can also reduce the need for animal testing.

19 rP-Sc in these tissues is the basis for live-animal testing.

20 mine the efficacy of lead compounds prior to animal testing.

21 sts, time requirements, and reliance on live animal testing.

22 but were strikingly absent from all southern animals tested.

23 gative for all other heterologous plants and animals tested.

24 hat differs from all previous cell types and animals tested.

25 urrent model, CNV was produced in 95% of the animals tested (19/20).

26 In addition, animals tested 24 h after receiving the lowest dose (0.1

27 rease in CTLp was maintained in five of five animals tested 6 months after transplant.

28 ly evident up to 60 min after PCP injection; animals tested 80 min after injection, when cortical dop

29 ely more stringent ethics and regulations on animal testing, a more practical and ethical alternative

30 eloped to address the challenges of reducing animal testing and assessing risks to the diversity of s

31 therapeutic approaches but also to mitigate animal testing and bridge the inter-species translationa

32 ural products should facilitate their use in animal testing and clinical trials.

33 is development, our approach can help reduce animal testing and contribute toward a new predictive ec

34 gs, cosmetics, and medical devices, reducing animal testing and extensive clinical trials.

35 od is a biologically relevant alternative to animal testing and offers advantages such as fast, easy

36 an be applied to future programs to minimize animal testing and promote more human-relevant chemical

37 Social pressure to minimize the use of animal testing and the ever-increasing concern on animal

38 idence of RVF infection was found in 9.2% of animals tested and across 23 districts of Kenya, reflect

39 s antidonor IgG was detected in four of four animals tested, and the 5-day mixed lymphocyte response

40 Despite the potential for extensive animal testing, animal welfare guidelines were not provi

41 l and economic concerns associated with live animal testing as well as the low throughput associated

42 AS-MOR rats was profound at 24 and 48 h, but animals tested at 72 h were similar to control groups.

43 However, RH animals tested at acute hypoglycemia ( approximately 2.8

44 blooms and brevetoxin was detected in 52% of animals tested at concentrations up to 500 ng/g.

45 DMT in baseline wake condition in 80% of the animals tested at levels comparable to serotonin and dop

46 ings and eliminated metastatic spread in all animals tested at the highest doses.

47 tizers by integrating data from multiple non-animal tests based on human cells, molecular targets, an

48 o be met before traditional cell culture and animal testing become obsolete.

49 olony-forming assays was equivalent in all 5 animals tested, but the in vivo levels of mononuclear ce

50 re independently validated by the SCGE small animal testing center to establish rigor and reproducibi

51 xicity, thus reducing expensive and invasive animal testing during clinical trials, for drugs that ar

52 In contrast, in animals tested during adolescence, there was no longer a

53 same behavior was unaffected by SCH 23390 in animals tested during the later stages of training.

54 Growing restrictions and bans on animal testing for chemical safety assessment under diff

55 t, which should ultimately result in reduced animal testing for drug development.

56 convenient and cost-effective alternative to animal testing for evaluating the regulation of mammalia

57 nization Act 2.0 "allows for alternatives to animal testing for purposes of drug and biological produ

58 a reliable and representative alternative to animal testing for the initial screening of SC formulati

59 may serve as a human-specific alternative to animal testing for the study of BM pathophysiology.

60 LC and NAcc of drug-paired and drug-unpaired animals tested for CPP, we observed no significant diffe

61 Aged animals tested for spontaneous locomotor activity were f

62 native cell system to PHHs, complementary to animal testing, for initial hepatotoxicity screening or

63 for developmental toxicants identified with animal testing guidelines (PPV = 72.4 and 77.3% during c

64 tion, classification, and labeling purposes, animal testing guidelines are required by law to evaluat

65 nsiderations related to conducting extensive animal testing have resulted in various initiatives to p

66 driven by new legislation, aimed at reducing animal testing in chemical risk assessment but mainly as

67 red to equally experienced and cocaine-naive animals tested in a novel environment.

68 istically in lesioned versus vehicle-treated animals tested in adulthood.

69 cts of these contaminants are assessed using animals tested in social isolation.

70 sults are consistent with the performance of animals tested in the visual domain.

71 y screening efficiency and reduce vertebrate animal testing, in vitro assays that identify chemical i

72 reased Ag-specific proliferation in half the animals tested, indicating a suppressive effect of gamma

73 ove towards a future in which less data from animal tests is required in the assessment of chemical s

74 For four of five animals tested, LF exhibited a triphasic kinetic profile

75 Across the animals tested, mean transmission efficiencies of -41.2,

76 In recent years, alternative animal testing methods such as computational and machine

77 zation Act 2.0's emphasis on alternative non-animal testing methods, our OASIS can serve as an animal

78 nd toll-like receptors 3 and 7 (TLR3/7), but animal testing needs to be conducted.

79 ssue and respiratory samples from uninfected animals tested negative on the Ultra.

80 eneficial responsiveness to fluoxetine in an animal test of antidepressant efficacy were strongly red

81 ther than behavioral changes in conventional animal tests of depression.

82 n, metabolism, excretion, and toxicity), and animal tests of these inhibitors.

83 sequencing, cloning, gene inactivation, and animal testing offers an efficient, rational, and rigoro

84 Preclinical animal testing often fails to predict adverse outcomes a

85 The high variability and expense of animal testing often makes it unfeasible to examine this

86 f cardiac AC was affected in all alpha i2-/- animals tested, only 50% of the alpha i2-/- animals show

87 e safety of novel drugs without resorting to animal testing or unwieldy computer simulations.

88 show adverse hepatic effects in preclinical animal tests or initial studies in man, it was later wit

89 y occlusion, yet it prevented VF in 10 of 11 animals tested (P<.001).

90 No animals tested PCR positive.

91 xfoliated cervicovaginal cells from 19 of 54 animals tested positive for at least one PV.

92 Two of eight (25%) animals tested positive from fallopian tube samples.

93 ds (26) was found to have potent activity in animal tests predictive of antipsychotic activity in hum

94 ieve sensitivities comparable to an approved animal testing protocol.

95 vailable for correlating results to approved animal testing protocols.

96 Zebrafish embryos are exempt from certain animal testing regulations, which facilitates their use

97 In an effort to reduce animal testing required by the gold standard method of b

98 years in residence in the United States, the animal tested serologically positive for B. equi by the

99 Large animal tests support the exceptional performance of the

100 Chlorthiazide's toxic dose for 50% of animals tested (TD50) could not be achieved even with do

101 esia but also support the validity of recent animal tests that are thought to capture aspects of epis

102 Surprisingly, in a portion of the animals tested, the BHV-1.1 gE and gI proteins functione

103 her, MPS represent more than alternatives to animal testing-they are strategic enablers of a human-re

104 In five of the nine animals tested, this slowly-decaying excitation could be

105 was partially suppressed in three-fourths of animals tested three months later, although one animal h

106 Addressing the shift from classical animal testing to high-throughput in vitro and/or simpli

107 ilure rate for the translation of drugs from animal testing to human treatments for TBI is 100%.

108 shift from primarily relying on traditional animal testing to incorporating advances in biotechnolog

109 sing cancer, regulatory toxicology relies on animal testing to predict carcinogenicity of chemicals,

110 -movement analysis could complement existing animal tests to improve preclinical drug development.

111 ) is a trace amine present in the CNS of all animals tested to date.

112 t for preclinical trials, commonly involving animal tests, to ascertain the safety of the compound pr

113 the pre-clinical testing process subject to animal testing upon adaptation in new drug discovery.

114 nical and ethical challenges associated with animal testing, we developed an in vitro assay that reca

115 be MRI safe by in vitro phantom and in vivo animal testing were enrolled.

116 isting information or through new vertebrate animal testing were voluntarily submitted by chemical co

117 Sixteen of 469 tolerant animals tested were found to have developed antidonor an

118 All animals tested were in renal failure, with blood urea ni

119 current hypoglycemia impaired performance in animals tested when hypoglycemic (45 +/- 4 vs. 55 +/- 2%

120 rate of full prevention is over 93% among 42 animals tested, which is a major leap in antiadhesion pe

121 ches are needed that decrease (or eliminate) animal testing while increasing predictivity.

122 totomy of the clamped arm occurred in 85% of animals tested, with 46% also autotomizing one or more o

123 Furthermore, on the challenge test, OVX+E animals tested without estrogen treatment continue to ex